Market Overview
The Peptide and Oligonucleotide CDMO Market is forecast to reach USD 3.5 billion in 2024, growing at a CAGR of 15.1% through 2034.
The peptide and oligonucleotide CDMO market has entered a period of accelerated commercialization driven by several converging factors: an expanding pipeline of drug candidates, increased regulatory clarity for GMP manufacturing, and strategic outsourcing by pharmaceutical sponsors. Market estimates place the combined market value in the low-to-mid single-digit billions (USD) in the mid-2020s, with projected double-digit growth over the next decade as demand for therapeutic-grade materials scales up.
Market Scope — Key Dimensions
- Service Range: End-to-end development services including process development, analytical method development, stability testing, and commercial GMP manufacturing for peptides and oligonucleotides.
- Modality Coverage: Short and long-chain peptides, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), aptamers, and conjugated oligonucleotides.
- Scale of Operations: From milligram-to-gram clinical lots to multi-kilogram commercial batches, requiring specialized expertise and facility design.
- Regulatory and Quality Focus: Strong emphasis on regulatory-compliant GMP production, impurity control, and robust analytical characterization, driving demand for experienced CDMO partners.
Key Growth Drivers
- Expanding Pipelines: Growth of ASOs, siRNA, and peptide therapeutics is increasing demand for outsourced manufacturing.
- Technical Complexity: Specialized chemistries and purification requirements favor CDMOs with advanced equipment and expertise.
- Strategic Outsourcing: Sponsors continue to shift non-core synthesis and scale-up work to external partners to reduce costs and accelerate time-to-clinic.
- Geographic Diversification: Increased CDMO capacity across regions allows sponsors options for cost, speed, and regulatory strategy.
Market Challenges
- Capacity Bottlenecks: Rapid pipeline growth can outpace available GMP manufacturing for certain oligonucleotide classes and longer peptides.
- Stringent Regulatory Requirements: Compliance with global GMP regulations for novel modalities requires significant investment.
- Raw Material Constraints: Specialty reagents, modified nucleotides, and chromatography resins can create supply-chain bottlenecks.
- Cost and Timeline Pressures: Sponsors expect fast turnarounds and competitive pricing, pressuring CDMO margins.
Market Opportunities
- Integrated Modality Platforms: Offering combined peptide/oligo services with analytics and conjugation capabilities.
- Clinical-to-Commercial Scale Bridges: Developing scalable processes that transfer efficiently from clinical to commercial production.
- Regional Expansion: Investing in Asia-Pacific and other emerging regions to capture cost-sensitive programs and growing biotech activity.
- Specialized Services: Providing high-purity long-peptide synthesis, nucleotide modifications, and automated analytics to command premium pricing.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market
Regional Analysis
- North America: Largest market by revenue due to the concentration of biotech sponsors and high per-project spend.
- Europe: Strong technical expertise and regulatory alignment support robust CDMO activity.
- Asia-Pacific: Fastest-growing region driven by increasing domestic biotech activity, cost-competitive services, and government incentives.
- Rest of World: Emerging markets are building capabilities, but high-value commercial manufacturing remains concentrated in major hubs.
Some of the major players
- Aurigene Pharmaceutical Services Ltd.
- Bachem Group
- CordenPharma
- Creative Peptides
- Curia Global, Inc.
- EUROAPI
- Genscript Biotech Corporation
- Lonza Group
- Merck KGaA
- PolyPeptide Group
- Senn Chemicals AG
- STA Pharmaceutical Co. Ltd.
- Sylentis, S.A.
- Thermo Fisher Scientific Inc.
- Wuxi AppTec
Market Outlook and Conclusion
The Peptide and Oligonucleotide CDMO market is projected to maintain sustained, above-market growth over the next decade. Key drivers include the expansion of RNA- and peptide-based therapeutic pipelines, the continued trend of outsourcing by pharmaceutical sponsors, and the growing need for GMP-compliant manufacturing capacity. CDMOs that offer technical expertise, integrated services, and scalable solutions are best positioned to capitalize on this dynamic and rapidly evolving market.
More Trending Latest Reports By Polaris Market Research:
Automotive Collision Repair Market
Powder Coating Equipment Market
Automotive Collision Repair Market
